• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • External Funding Opportunities
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
    • Medical Oncology
    • Nuclear Medicine
    • Pathology
    • Radiation Oncology
    • Radiology
    • Urologic Oncology
    • Research Faculty
    • Emeritus Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. High-intensity Focused Ultrasound Study

High-intensity Focused Ultrasound Study

Share this

High-intensity Focused Ultrasound Study
Lay title: An Observational Study to Learn More About Using High-Intensity Focused Ultrasound for the Removal of Prostate Tissue

Technical title: High-Intensity Focused Ultrasound for Focal Ablation of Prostate Tissue: An Observational Study of Multiparametric MRI and Ultrasound Fusion Imaging for Guidance

Disease Type:Prostate Cancer

Basic Information:The purpose of this observational research study is to collect and analyze clinical data from patients before and after receiving HIFU (High Intensity Focused Ultrasound). HIFU is an FDA-approved tool used to ablate prostate tissue. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015.

Research Procedures (not a complete list): Upon obtaining subjects’ informed consent to participate in the study, they will agree to the collection of clinical data for research purposes, and be asked to complete optional pre- and post-treatment questionnaires about quality-of-life data and decision-making.  

Eligibility Criteria (not a complete list):
Inclusion Criteria:

  • Age 40-85.
  • Has elected or already undergone HIFU therapy as their prostate cancer treatment and declined alternative treatment (such as active surveillance, radiation therapy, etc.).
  • PSA ≤ 20.

Exclusion Criteria:

  • Prior treatment for prostate cancer other than androgen deprivation therapy.
  • Unable to tolerate anesthesia.
  • Unable to complete follow-up MRIs or prostate biopsies.

For More Detailed Information, Contact:

  • Leonard Marks, MD, Principal Investigator, Professor of UCLA Urology 
  • Merdie Delfin, NP, Study Coordinator, (310) 794-3566
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest